text: <unk>  is an interleukin-5 antagonist monoclonal antibody (IgG1 kappa) that is FDA approved for the treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype (indicated for add-on maintenance treatment).   Common adverse reactions include headache, injection site reaction, back pain, and fatigue (5%).
option_0: Mepolizumab
option_1: Vedolizumab
option_2: Certolizumab pegol
option_3: Natalizumab
option_4: Belatacept
option_5: Reslizumab
option_6: Eculizumab
option_7: Emicizumab